META ANALYSIS

GROUP B
PROPOSAL

BLANCO, ATHENA JUNE

DELICANA, DONNA VIE
MILANES, WALLIE FRED
• Coronavirus Disease (COVID-19) is an
infectious disease caused by novel coronavirus
designated as severe acute respiratory
syndrome coronavirus 2 ( SARS-CoV-2).
• Most people infected with COVID 19 virus will
experience mild to moderate respiratory
illness and recover without special treatment.
• Favipiravir was first used against SARS- CoV 2 in
Wuhan, China at the very epicentre of the pandemic.
• Favipiravir is a synthetic prodrug, first discovered
while assessing the antiviral activity of chemical
agents active against the influenza virus
• Favipiravir acts as a nucleotide analog that selectively
inhibits the viral RNA dependent RNA polymerase or
causes lethal mutagenesis upon incorporation to the
virus
TITLE:
EFFICACY OF FAVIPIRAVIR IN MILD TO
MODERATE COVID- 19: A SYSTEMATIC REVIEW
AND META- ANALYSIS
Research Question

• Efficacy of Favipiravir in Mild to Moderate

COVID- 19 versus placebo and standard of
care in reducing mortality and morbidity.
Objective:

• To determine the efficacy of Favipiravir in

Mild to Moderate COVID- 19 cases.
INCLUSION AND EXCLUSION CRITERIA:

DATE: JUNE 2020- JUNE 2021

EXPOSURE OF INTEREST: COVID- 19 patients (Mild to
Moderate admitted patient)
LANGUAGE: English
PARTICIPANTS: Cochrane Library, PubMed, Elsevier,
WHO (COVID 19 Global Literature on Coronavirus
disease) Clinical Trials.gov.MedRvix
SETTING: Hospital Admitted patients
STUDY DESIGN: Randomized Clinical Trials
Pre- Specified Eligibility Criteria:

TYPES OF PARTICIPANTS:
- Mild to Moderate COVID- 19 patients
- Adult patients ( Ages 18 and above)
- Female or Male
- Hospital Setting
Pre- Specified Eligibility Criteria:

POPULATION ATTRIBUTES EXAMPLE OF POPULATION

INTENDED RECIPIENT OF INTERVENTION  PATIENT
 HEALTHCARE PROVIDER
 COMMUNITY

DISEASE/ CONDITION MILD TO MODERATE CASES COVID 19

PARTICIPANTS CHARACTERISITICS  ADULTS ( 18 YEARS OLD AND
ABOVE)
 FEMALE
 MALE

SETTING HOSPITAL/ WARD ADMISSION

TYPES OF INTERVENTION:

- Favipiravir dosage 1800 mg/tab BID x 1 day then 800

mg/tab BID x 13 days vs. placebo and standard of
care
- Dosage specific and time specific (administered for 14
days)
 STEP CONSIDERATIONS
1. Identify intervention - Availability of the product
characteristics that may modify - Adverse/ Side effects
the effect of the intervention - Intolerance
- Withdrawal/Non Compliance
SELECTING, PRIORITIZING AND GROUPING REVIEW OUTCOMES

- Reduce mortality and morbidity of Mild to Moderate COVID-19 cases

Critical Outcome:
A. Reduce mortality of Mild to Moderate COVID- 19 cases by using Favipiravir
standard dose
B. Reduce morbidity of Mild to Moderate COVD-19 cases by using Favipiravir
standard dose
C. Intolerance/noncompliance and Withdrawal to Favipiravir standard dose during
the course of treatment will not give reduction to mortality and morbidity of the
Mild to Moderate COVID- 19 cases
D. Cost effectiveness of using Favipiravir versus Standard of care as treatment for
Mild to Moderate COVID 19 cases
E. Long term effects of Favipiravir as treatment for Mild to Moderate COVID 19
cases as for the quality of life of the patient
STUDY DESIGNS

- Randomized Clinical Trial (RCTs)

SEARCHING AND SELECTING STUDIES

DATABASES: Cochrane Review Group’s ( CRG’s)

- CENTRAL (Cochrane Central Register of Controlled Trials)
- MEDLINE
- EMBASE
• HINARI (Health Inter Network Access to Research Initiative)

Bioliographic Databases:
- LILACS

Searching Trial Registers

- ClinicalTrials.gov
- WHO International Clinical Trials Registry Platform (ICTRP)
Designing Search Strategies:

PICO FORMAT
P: Mild to Moderate COVID 19 Infection
I: Favipiravir
C: Versus Placebo and Standard of Care treatment
O: Reduced Mortality or Morbidity

Search Strategy:
I. terms to search for the health condition of interest ( e.g.
population)
II. terms to search for the intervention (s) evaluated
III. terms to search for the types of study design to be included
 
Timing of Searches:
- Within 12 month period ( June 2020- June 2021)
Search Filters:
- Cochrane Highly Sensitive Search Strategies for
identifying Randomized trial in MEDLINE
Peer Review of Search Strategies:
- PRESS Evidence- Based Checklist
Documenting and Reporting the Search Process:

- Guidance for medical/ healthcare librarian or information specialist for

documentation
- For Cochrane Reviews, the bibliographic database search strategies should be
copied and pasted into an appendix exactly as run an in full, together with
the search set numbers and the total number of records retrieved by each
search strategy.
- Offline copy in text format should be saved; saving screenshot of the search
may also be used
- Save locally or file print copies of any information found on the internet, such
as information about ongoing and/or unpublished trials, as this information
may no longer be accessible at the time the review is written
- PRISMA flow diagram for details of flow of studies from the numbers of
references identified in the search to the number of studies included in the
review which will be included in the final review (PRISMA Flow Diagram
Generator)
Identifying Multiple Reports:

-Trial Identification Numbers

-Authors names
-Location and setting
-Specific details of the interventions
-Specific Details of the Interventions
- Number of Participants
- Date and Duration of the Study
Typical Process for Selecting Studies:

1. Merge search results from different sources using reference management

software, and remove duplicate records of the same report.
2. Examine titles and abstracts to remove obviously irrelevant reports.
3. Retrieve the full text of the potentially relevant reports.
4. Link together multiple reports of the same study.
5. Examine full- text reports for compliance of studies with eligibility criteria
6. Correspond with investigators, where appropriate, to clarify study
eligibility (it may be appropriate to request further information, such as
missing methods information or results, at the same time).
7. Make final decisions on study inclusion and proceed to data collection
8. Tag or record any ongoing trials which have not yet been reported so that
they can be added to the ongoing studies table.
Selecting “Excluded Studies”:
- Use of other intervention other than Favipiravir
- Severe to Critical COVID 19 cases
 
Software support for Selecting Studies:
o Abstrackr
o Covidence
o DistillerSR
o EPPI- Reviewer
o Rayyan
• Thank you.